Andrew ElBardissi, M.D., is a Partner on Deerfield's Medical Technologies team and joined the firm in 2017. Before Deerfield he was a Principal at Longitude Capital, focused on medtech and biotechnology investments, and before that an Associate in JPMorgan's healthcare investment banking practice. He received residency training in General Surgery at Harvard Medical School's Brigham and Women's Hospital and in Cardiothoracic Surgery at Stanford University, has been funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, and has authored over 30 publications in peer-reviewed journals. He holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology from the Schreyer Honors College at the Pennsylvania State University. SEC Form D filings name him as a director of Medical Microinstruments, Inc. and, as of July 2025, of Adela, Inc.
Education
Pennsylvania State University, Schreyer Honors College, B.S. with honors in Biology
Mayo Clinic, M.D.
Harvard University, M.P.H. in Quantitative Methods
Longitude Capital - Principal, medtech and biotechnology investments
Notable Investments
Medical Microinstruments, Inc.Adela, Inc.
Board Seats
Director, Medical Microinstruments, Inc. - Named as a Director in the issuer's Form D filed 4 March 2024, the most recent first-party filing naming the company's directors that was found. Medical Microinstruments is listed on Deerfield's own portfolio page.
Career Timeline
2017
Joins Deerfield as a Partner on the Medical Technologies team.
2024
Named as a Director of Medical Microinstruments, Inc. in the issuer's Form D filed 4 March 2024.
2025
Named as a Director of Adela, Inc. in the issuer's Form D filed 8 July 2025; he is not named in Adela's Form D filed 23 April 2026, which lists Abraham Kometz as a Director instead.